Brooks Laboratories: Should You Buy, Hold, or Sell Right Now?

Brooks Laboratories share price Rs 64.75 (NSE), up nearly 3% today, well off its 52-week high. 52-week range Rs 36.90 to Rs 162.80. Q1 FY27 swung to a loss after a declining quarterly trend.

Updated: 11 Sept 2026 • 9:33 am

Posted by:

Brooks Laboratories: Should You Buy, Hold, or Sell Right Now?

Quick Answer

Brooks Laboratories Ltd share price is trading around Rs 65, up nearly 3 percent today, roughly 60 percent below its 52-week high of Rs 162.80 but well above its 52-week low of Rs 36.90. Q1 FY27 revenue fell 10.1 percent year on year to Rs 23.14 crore, with the company swinging to a net loss of Rs 1.79 crore from a profit of Rs 9.58 crore a year earlier, part of a consistently declining quarterly trend across the past year. Full-year FY26 revenue grew 4.2 percent, with the company turning a profit of Rs 24.58 crore, a genuine annual turnaround from a net loss of Rs 9.97 crore in FY25. Given the negative trailing quarterly earnings, investors should focus on the underlying quarterly trend rather than the annual turnaround alone.

Brooks Laboratories share price is up nearly 3 percent today, trading around Rs 65 on the NSE, roughly 60 percent below its 52-week high of Rs 162.80, well above its 52-week low of Rs 36.90. Given a genuine annual turnaround in FY26 alongside a consistently declining and now negative quarterly trend, this article presents the numbers plainly before laying out a careful, balanced view.

This Brooks Laboratories stock analysis walks through the declining quarterly trend despite the FY26 annual turnaround, valuation considerations, shareholding pattern and the technical setup, using figures sourced from public filings.

Click Here – Get Free Investment Predictions

Table of Contents

About Brooks Laboratories

Keep this backdrop in mind when reading the rest of this Brooks Laboratories share price review. Before deciding on Brooks Laboratories share price, it helps to understand the underlying business. Brooks Laboratories Ltd. manufactures sterile pharmaceutical formulations, including ophthalmic and other injectable products, serving domestic and export markets.

As a sterile pharmaceutical formulations manufacturer, Brooks Laboratories achieved a genuine annual turnaround in FY26, but the underlying quarterly trend has been consistently declining across the past year, culminating in a swing to a loss in the most recent quarter, a pattern that deserves plain attention despite the annual headline.

Brooks Laboratories Share Price Today: Key Levels

The table below summarises where Brooks Laboratories share price stands right now against its recent trading range and market value.

Metric	Value
Brooks Laboratories CMP (NSE)	Rs 64.75
Brooks Laboratories CMP (BSE)	Rs 65.00
52-Week High	Rs 162.80
52-Week Low	Rs 36.90
Market Capitalisation	Approximately Rs 187 crore

Brooks Laboratories share price is up today, though it remains well below its 52-week high, reflecting the market's caution around the consistently declining quarterly trend.

Check the Univest Screener for Live Stock Data

Brooks Laboratories Financial Performance

Track this line item closely if you are following Brooks Laboratories share price closely. The Brooks Laboratories share price trend is closely tied to how these numbers evolve each quarter. Brooks Laboratories reported Q1 FY27 (June 2026 quarter) revenue of Rs 23.14 crore, down 10.1 percent year on year from Rs 25.73 crore, with the company swinging to a net loss of Rs 1.79 crore from a profit of Rs 9.58 crore a year earlier. This continued a consistently declining quarterly trend: Rs 9.58 crore, Rs 7.98 crore, Rs 5.50 crore, Rs 1.52 crore, and now a loss of Rs 1.79 crore.

For the full year FY26, the company reported revenue of Rs 86.91 crore, up 4.2 percent year on year, with net profit of Rs 24.58 crore, a genuine turnaround from a net loss of Rs 9.97 crore in FY25, though this annual figure was driven substantially by the stronger quarters earlier in the year before the subsequent quarterly deterioration.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 23.14 crore	Net loss Rs 1.79 crore	Revenue -10.1%; reversed from a profit YoY, fifth consecutive declining quarter
FY26 (full year)	Rs 86.91 crore	Rs 24.58 crore	+4.2% revenue; turned around from a Rs 9.97 crore loss in FY25

Valuation Check: Is Brooks Laboratories Share Price Expensive?

It is one of the clearest signals available on Brooks Laboratories share price today. Any view on Brooks Laboratories share price should start from these valuation multiples. Given Brooks Laboratories' negative most recent quarterly earnings, the trailing price to earnings ratio of about 41.06 times, a discount to the broader pharmaceutical sector average of roughly 51.5 times, is based on the stronger FY26 annual figure and does not yet reflect the recent quarterly deterioration.

The price to book ratio stands near 1.6 times, with return on equity at 4.80 percent. Debt to equity of 0.07 is low. Given the consistently declining quarterly trend, investors should treat the current trailing PE with caution and focus on whether the company can reverse the recent losses.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Brooks Laboratories share price. Brooks Laboratories share price is up nearly 3 percent today, positioned roughly 60 percent below its 52-week high of Rs 162.80, well above its 52-week low of Rs 36.90. A stock trading here after such a significant decline often reflects the market pricing in the consistently declining quarterly trend that culminated in the recent loss.

Trading volumes remain moderate, so investors should track Brooks Laboratories share price alongside the company's next quarterly disclosure for signs of stabilisation, rather than assuming today's move alone signals a reversal of the declining trend.

Download the Univest iOS App or Univest Android App to track Brooks Laboratories' live price and technical levels.

Shareholding Pattern

Shifts here can influence Brooks Laboratories share price more than headline news on some sessions. Brooks Laboratories is a promoter-led sterile pharmaceutical formulations manufacturer with low leverage, currently facing a consistently declining quarterly trend. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Brooks Laboratories

Genuine FY26 annual turnaround: The company moved from a net loss in FY25 to a solid annual profit in FY26, showing the business has periods of strong execution.
Low financial leverage: A debt to equity ratio of just 0.07 gives the company financial flexibility to manage the current quarterly softness.
Sterile formulations niche positioning: As a manufacturer of sterile ophthalmic and injectable formulations, the company holds a differentiated niche within the broader pharmaceutical sector.

Risks and Factors to Watch

Consistently declining quarterly trend: Quarterly profit has declined for five consecutive quarters, from Rs 9.58 crore to a loss of Rs 1.79 crore, a real and serious deterioration that the FY26 annual headline does not fully capture.
Swing to a quarterly loss: The most recent quarter reversed to a net loss from a profit a year earlier, confirming the declining trend has now become negative.
Very significant decline from 52-week high: The stock has fallen roughly 60 percent from its high, and investors should understand the reasons behind this decline before assuming the current level represents value.
Sterile pharmaceutical formulations sector competitive pressure: Brooks Laboratories competes against other domestic and international sterile pharmaceutical formulations manufacturers.

Brooks Laboratories Share Price Target: What the Data Suggests

Until then, Brooks Laboratories share price remains best tracked through live, verified data rather than a single fixed number. Given Brooks Laboratories' consistently declining quarterly trend, no reliable analyst price target framework applies to this stock at this time.

Investors considering this stock should track the Univest Screener for continued quarterly updates on whether the decline stabilises, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.

Brooks Laboratories: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Brooks Laboratories share price right now. The Brooks Laboratories buy or sell decision should focus on the declining quarterly trend rather than the FY26 annual headline.

The case for buying: Only investors who believe the recent quarterly decline is temporary and see potential for stabilisation may consider a position, given the very significant decline from the 52-week high.

The case for holding: Existing shareholders who already accept this volatility may choose to continue monitoring for signs the decline has bottomed.

The case for waiting: Most investors would reasonably prefer to wait for the quarterly trend to stabilise or reverse before committing fresh capital.

Given the declining trend here, consult a SEBI-registered investment adviser before proceeding.

Conclusion

Brooks Laboratories share price reflects a sterile pharmaceutical formulations manufacturer that achieved a genuine FY26 annual turnaround, even as the underlying quarterly trend has consistently declined into a loss over the past year, trading well below its 52-week high. This article is for informational purposes and not a personalised investment recommendation.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Q1. Is Brooks Laboratories a good stock to buy right now?

Ans. Brooks Laboratories achieved a genuine FY26 annual turnaround to a Rs 24.58 crore profit, but its quarterly trend has declined for five consecutive quarters, swinging to a loss in Q1 FY27. This suits only investors who believe the recent decline is temporary.

Q2. What is the Brooks Laboratories share price today?

Ans. Brooks Laboratories share price is trading around Rs 65 on the NSE, up nearly 3 percent today. The stock's 52-week high is Rs 162.80 and its 52-week low is Rs 36.90.

Q3. What is the Brooks Laboratories share price target?

Ans. Given Brooks Laboratories' consistently declining quarterly trend, no reliable analyst price target framework applies to this stock at this time.

Q4. Is Brooks Laboratories profitable?

Ans. Brooks Laboratories achieved a full-year FY26 profit of Rs 24.58 crore, a genuine turnaround from a loss in FY25, but the most recent Q1 FY27 quarter swung to a net loss of Rs 1.79 crore, part of a five-quarter declining trend.